title: Pharmacological therapy after acute cervical spinal cord injury.
abstract: There is insufficient evidence to support treatment standards.
  
  
  
  There is insufficient evidence to support treatment guidelines.
  
  
  
  Treatment with methylprednisolone for either 24 or 48 hours is recommended as an option in the treatment of patients with acute spinal cord injuries that should be undertaken only with the knowledge that the evidence suggesting harmful side effects is more consistent than any suggestion of clinical benefit. GM-1 GANGLIOSIDE:
  
  
  
  There is insufficient evidence to support treatment standards.
  
  
  
  There is insufficient evidence to support treatment guidelines.
  
  
  
  Treatment of patients with acute spinal cord injuries with GM-1 ganglioside is recommended as an option without demonstrated clinical benefit.
authors.forename: M N
authors.initials: MN
authors.lastname: Hadley
authors.forename: B C
authors.initials: BC
authors.lastname: Walters
authors.forename: P A
authors.initials: PA
authors.lastname: Grabb
authors.forename: N M
authors.initials: NM
authors.lastname: Oyesiku
authors.forename: G J
authors.initials: GJ
authors.lastname: Przybylski
authors.forename: D K
authors.initials: DK
authors.lastname: Resnick
authors.forename: T C
authors.initials: TC
authors.lastname: Ryken
mesh_terms: D000208:Acute Disease; D002574:Cervical Vertebrae; D019091:Critical Pathways / Q000592:standards; D019317:Evidence-Based Medicine; D005677:G(M1) Ganglioside / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic / Q000592:standards; D013119:Spinal Cord Injuries / Q000188:drug therapy*
chemical_list: D005677:G(M1) Ganglioside; D008775:Methylprednisolone